Scalper1 News
IBD’s Big Cap Leaders screen filters through highly liquid, large-cap stocks with a strong record of earnings growth. Eight top-notch medical stocks that made the screen’s cut are Valeant Pharmaceuticals (VRX), Gilead Sciences (GILD), Celgene (CELG), Actavis (ACT), Biogen (BIIB), Regeneron (REGN), Shire (SHPG) and Illumina (ILMN). Valeant Pharmaceuticals has a highest-possible IBD Composite Rating of 99, meaning its shares outperform 99% of all Scalper1 News
Scalper1 News